SCHEMBL9428481

SCHEMBL9428481

Cc1cccc2c1ccn2-c1ccccc1C#N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.46
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
KDM4E B2RXH2 2/20 0.40
KMT2A Q03164 1/20 0.40
XIAP P98170 1/20 0.38
IMPDH2 P12268 1/20 0.38
HTR7 P34969 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR3A P46098 1/20 0.36
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15565198 0.78 HTR7 (0.40) KDM4EKMT2AXIAPIMPDH2HTR7
SCHEMBL9429028 0.78 HTR7 (0.47) TSHRKDM4EKMT2AXIAPHTR7
SCHEMBL9343076 0.78 XIAP (0.44) TSHRKMT2AXIAPHTR7HTR3A
SCHEMBL28894100 0.78 HTR2A (0.41) TSHRCYP1A2KDM4EHTR7HTR2A
SCHEMBL8926318 0.77 HTR3A (0.45) TSHRKMT2AXIAPHTR7HTR3A
SCHEMBL31454929 0.76 HTR2A (0.43) TSHRCYP1A2KDM4EKMT2AHTR2A
SCHEMBL28162250 0.76 TSHR (0.46) TSHRCYP1A2CYP2C19KDM4EKMT2A
SCHEMBL699112 0.76 BIRC5 (0.43) TSHRKDM4EKMT2AIMPDH2HTR7
SCHEMBL30097476 0.76 BIRC5 (0.43) TSHRKDM4EKMT2AIMPDH2HTR7
SCHEMBL9429932 0.75 TSHR (0.44) TSHRCYP1A2CYP2C19KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394263-B2 Substituted hetero-azepinones F. HOFFMANN-LA ROCHE AG (CH) 2016-07-19 US claimed
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES HOFFMAN-LA ROCHE INC. (US) 2015-12-17 US claimed
US-9394263-B2 Substituted hetero-azepinones F. HOFFMANN-LA ROCHE AG (CH) 2016-07-19 US disclosed
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES HOFFMAN-LA ROCHE INC. (US) 2015-12-17 US disclosed
US-5374615-A Treating hypertension and congestive heart failure, preventing cardiac hypertrophy E. R. SQUIBB & SONS, INC. (US) 1994-12-20 US disclosed
EP-0547827-A1 Indole and benzimidazole-substituted dihydropyrimidine derivatives useful as A-II receptors antagonists E.R. SQUIBB & SONS, INC. (US) 1993-06-23 EP disclosed
US-5212177-A INDOLE AND BENZIMIDAZOLE-SUBSTITUTED DIHYDROPYRIMIDINE DERIVATIVES E. R. SQUIBB & SONS, INC. (US) 1993-05-18 US disclosed
EP-0488532-A1 Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives E.R. Squibb & Sons, Inc. (US) 1992-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES CCNY, CCNE1, CCND3 TSHR 1000/4885CYP1A2 544/4885CYP2C19 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.